Archives of Virology

, Volume 98, Issue 3–4, pp 137–153 | Cite as

Zwitterionic detergent solubilisation of HSV-1 surface antigens

  • R. Jennings
  • T. Quasim
  • R. M. Sharrard
  • D. Hockley
  • C. W. Potter
Original Papers
Received:
Accepted:

Summary

A preparation was obtained from herpes simplex virus type 1 (HSV-1)-infected cells using a zwitterionic detergent, Empigen BB. The preparation was partially-purified either by ultracentrifugation over a cushion of 20% sucrose or on a sucrose density gradient. Partial characterisation of these materials by ELISA, using both polyclonal and monoclonal antibodies showed them to contain at least four major HSV glycoproteins, gB, gC, gD and gE. Comparison of Empigen-extracted HSV-1 antigen preparations with preparations obtained using the non-ionic detergents Nonidet P40 or Triton-X-100 indicate that, using conventional procedures, separation of glycoproteins, B, C, D, and E from unwanted proteins may be facilitated using the former detergent.

Immunization of mice with Empigen-extracted, partially-purified or gradient-purified antigen preparations elicited good levels of antibody detectable by ELISA and a high degree of protection against both HSV-1 and HSV-2 challenge infection. Such protection could be achieved using aqueous antigen preparations, but was augmented using aluminium hydroxide gel as an adjuvant. In general, Empigen-extracted HSV-1 antigen preparations elicited higher ELISA antibody levels and more complete protection against HSV challenge infection than NP40 or Triton-X-100-extracted preparations.

The value and usefulness of the detergent Empigen for obtaining HSV surface antigen preparations and the role of these as potential vaccines against HSV infections, is discussed.

Keywords

Herpes Simplex Surface Antigen Aluminium Hydroxide Sucrose Density Gradient Complete Protection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Allen JC, Humphries C (1975) The use of zwitterionic surfactants in the agarose chromatography of biological membranes. FEBS Lett 57: 158–162Google Scholar
  2. 2.
    Ashley R, Mertz G, Clark H, Schick M, Salter D, Corey L (1985) Humoral immune response to Herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine. J Virol 56: 475–481Google Scholar
  3. 3.
    Buckmaster EA, Gompels U, Minson A (1984) Characterisation and physical mapping of an HSV-1 glycoprotein of approximately 115 × 103 molecular weight. Virology 139: 408–413Google Scholar
  4. 4.
    Burton K (1955) A study of the conditions and mechanisms of the diphenylamine reaction for the colorimetric estimation of deoxyribunucleic acid. Biochem J 62: 315–323Google Scholar
  5. 5.
    Cappel R, De Cuyper F, Rikaert F (1980) Efficacy of a nucleic acid free subunit vaccine. Arch Virol 65: 381–385Google Scholar
  6. 6.
    Cappel R, Sprecher S, De Cuyper F (1982) Immune responses to DNA free Herpes simplex proteins in man. Dev Biol Stand 52: 345–350Google Scholar
  7. 7.
    Chan WL (1983) Protective immunization of mice with specific HSV-1 glycoproteins. Immunology 49: 343–352Google Scholar
  8. 8.
    Corey L, Spear PG (1986) Infections with Herpes simplex virus. N Engl J Med 314: 749–757Google Scholar
  9. 9.
    Crawford CR, Mukhlis FA, Jennings R, Oxford JS, Hockley DJ, Potter CW (1984) Use of a zwitterionic detergent for the disruption of influenza virus. I. Preparation and characterisation of disrupted virions. Vaccine 2: 193–198Google Scholar
  10. 10.
    Cremer KJ, Mackett M, Wohlenberg C, Notkins AL, Moss B (1985) Vaccinia virus recombinant expressing Herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science 228: 737–740Google Scholar
  11. 11.
    Dix RD, Mills J (1985) Acute and latent Herpes simplex virus neurological disease in mice immunised with purified virus-specific glycoproteins gB or gD. J Med Virol 17: 9–18Google Scholar
  12. 12.
    Dulley JR, Grieve PA (1975) A simple technique for eliminating interference by detergents in the Lowry method of protein determination. Ann Biochem 64: 136–141Google Scholar
  13. 13.
    Dyke SF, Williams W, Seto JT (1978) Glycoproteins of representative paramyxoviruses: isolation and antigenic analysis using a zwitterionic surfactant. J Med Virol 2: 143–152Google Scholar
  14. 14.
    Eisenberg RJ, Cerini CP, Heilman CJ, Joseph AD, Dietzschold B, Golub E, Long D, Ponce de Leon M, Cohen GH (1985) Synthetic glycoprotein D-related peptides protect mice against Herpes simplex virus challenge. J Virol 56: 1014–1017Google Scholar
  15. 15.
    Eisenberg RJ, Ponce de Leon M, Pereira L, Long D, Cohen GH (1982) Purification of glycoprotein D of Herpes simplex virus types 1 and 2 by use of monoclonal antibody. J Virol 41: 1099–1104Google Scholar
  16. 17.
    Gell PGH, Moss PAH (1985) Production of cell-mediated response to Herpes simplex virus by immunisation with anti-idiotypic heteroantisera. J Gen Virol 66: 1801–1804Google Scholar
  17. 17.
    Hilfenhaus J, Christ H, Kohler R, Moser H, Kirchner H, Levy HB (1981) Productivity of Herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence. Med Microbiol Immunol 169: 225–235Google Scholar
  18. 18.
    Hilfenhaus J, Moser H (1981) Prospects for a subunit vaccine against Herpes simplex virus infections. Behring Inst Mitt 68: 45–56Google Scholar
  19. 19.
    Hsu M-C, Scheid A, Choppin PW (1979) Reconstitution of membranes with individual paramyxovirus glycoproteins and phospholiplids in cholate solution. Virology 95: 476–491Google Scholar
  20. 20.
    Kino Y, Eto T, Nishiyama K, Ohtomo N, Mori R (1986) Immunogenicity of purified glycoprotein gB of Herpes simplex virus. Arch Virol 89: 69–80Google Scholar
  21. 21.
    Kitces EN, Morahan PS, Tew JG, Murray BK (1977) Protection from oral Herpes simplex virus infection by a nucleic acid-free virus vaccine. Infect Immun 16: 955–960Google Scholar
  22. 22.
    Klein RJ, Kaley LA, Friedman-Kien AE (1984) Protection against establishment of latent infection in mice immunised with a non-pathogenic herpes simplex virus mutant and reinfected with the pathogenic parental strain. Vaccine 2: 219–223Google Scholar
  23. 23.
    Koszinowski UH, Allen H, Gething MJ, Waterfield MD, Klenk HD (1980) Recognition of viral glycoproteins by influenza-A specific cross-reactive cytolytic T lymphocytes. J Exp Med 151: 945–958Google Scholar
  24. 24.
    Kutinova L, Vonka V, Slichtova V (1980) Immunogenicity of subviral herpes simplex virus preparations: protection of mice against intraperitoneal infection with liv herpes. Acta Virol 24: 391–398Google Scholar
  25. 25.
    Long D, Madara TJ, Ponce de Leon, Cohen GH, Montgomery PC, Rosenberg RJ (1984) Glycoprotein D protects mice against lethal challenge with Herpes simplex virus types 1 and 2. Infect Immun 37: 761–764Google Scholar
  26. 26.
    Lowry O, Rosebrough NJ, Farr AL, Randall TJ (1951) Protein measurements with the Folin phenol reagent. J Biol Chem 193: 265–275Google Scholar
  27. 27.
    Meignier B, Jourdier TM, Norrild B, Pereira L, Roizman B (1987) Immunisation of experimental animals with reconstituted glycoprotein mixtures of Herpes simplex virus 1 and 2: protection against challenge with virulent virus. J Infect Dis 155: 921–930Google Scholar
  28. 28.
    Mertz GJ, Peterman G, Ashley R, Jourden JL, Salter D, Morrison L, McLean A, Corey L (1984) Herpes simplex virus type-2 glycoprotein-subunit-vaccine: tolerance and humoral and cellular responses in humans. J Infect Dis 150: 242–249Google Scholar
  29. 29.
    Mukhlis FA, Crawford CR, Jennings R, Potter CW (1984) Use of a zwitterionic detergent for the preparation of an influenza virus vaccine: 2. Immunogenicity of Empigen-treated virus in animals. Vaccine 2: 199–203Google Scholar
  30. 30.
    Mukhlis FA, Jennings R, Stephenson TJ, Quasim T, Potter CW (1986) Characterisation and immunogenicity of HSV-1 antigens obtained following zwitterionic detergent treatment. Vaccine 4: 191–196Google Scholar
  31. 31.
    Najem S, Barton IG, Al-Omer LS, Potter CW (1982) Antibody to Herpesvirus hominis in patients with carcinoma of the cervix. Br J Exp Pathol 63: 485–489Google Scholar
  32. 32.
    Nilheden E, Jeansson S, Vahlne A (1983) Typing of Herpes simplex virus by an enzymelinked immunosorbent assay with monoclonal antibodies. J Clin Microbiol 17: 677–680Google Scholar
  33. 33.
    Olofsson S, Sjoblom I, Lundstrom M, Jeansson S, Lycke E (1983) Glycoprotein C of Herpes simplex virus Type 1: characterisation of O-linked oligosaccharides. J Gen Virol 64: 2735–2747Google Scholar
  34. 34.
    Plummer G, Waner JL, Bowling CP (1968) Comparative studies of type 1 and type 2 Herpes simplex viruses. Br J Exp Pathol 49: 202–208Google Scholar
  35. 35.
    Rawls WE, Iwamoto K, Adam E, Melnick JC (1970) Measurement of antibodies to Herpesvirus type 1 and 2 in human serum. J Immunol 104: 599–606Google Scholar
  36. 36.
    Reid VW, Longman GF, Heinerth E (1967) Determination of anionic-active detergents by two-phase titration. Tenside 9: 292–304Google Scholar
  37. 37.
    Roberts PL, Duncan BE, Raybould TJG, Watson DH (1985) Purification of Herpes simplex virus glycoprotein B and C using monoclonal antibodies and their ability to protect mice against lethal challenge. J Gen Virol 66; 1073–1085Google Scholar
  38. 38.
    Scriba M (1982) Animal studies on the efficiency of vaccination against recurrent herpes. Med Microbiol Immunol 171: 33–42Google Scholar
  39. 39.
    Schrier RD, Pizer LI, Moorhead JW (1983) Type specific delayed hypersensitivity and protective immunity induced by isolated Herpes simplex virus glycoproteins. J Immunol 130: 1413–1418Google Scholar
  40. 40.
    Skinner GRB, Williams DR, Buchan A, Whitney J, Harding M, Bodfish K (1978) Preparation and efficacy of an inactivated subunit vaccine (HFU BHK) against type-2 Herpes simplex virus infection. Med Microbiol Immunol 166: 119–132Google Scholar
  41. 41.
    Skinner GRB, Woodman CBJ, Hartley CE, Buchan A, Fuller A, Durham J, Synnot M, Clay JC, Melling J, Wibling C, Wilkins J (1982) Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of Herpes genitalis. Br J Venereal Dis 58: 381–386Google Scholar
  42. 42.
    Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG (1987) Vaccination with recombinant Herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 155: 914–920Google Scholar
  43. 43.
    Vestergaard BF, Grauballe PC, Spanggaard H (1977) Titration of Herpes simplex antibody in human sera by the enzyme-linked immunosorbent assay (ELISA). Acta Pathol Microbiol Scand [B] 85: 466–468Google Scholar
  44. 44.
    Watari E, Dietzschold B, Szokan G, Heber-Katz E (1987) A synthetic peptide induces long-term protection from lethal infection with Herpes simplex virus-2. J Exp Med 165: 459–470Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • R. Jennings
    • 1
  • T. Quasim
    • 1
  • R. M. Sharrard
    • 1
  • D. Hockley
    • 2
  • C. W. Potter
    • 1
  1. 1.Department of VirologyUniversity of Sheffield Medical SchoolSheffield
  2. 2.National Institute of Biological Standards and ControlSouth MimmsU.K.

Personalised recommendations